PeopleBio피플바이오
304840 · KOSDAQ · ₩304840 · 피플바이오
₩561 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 15.5% | −16.3% | 36.2% | 31.5% | 30.5% | −133.7% |
| Operating margin | −165.5% | −293.9% | −308.2% | −342.4% | −263.2% | −1,253.8% |
| Net margin | −421.0% | −551.3% | −292.5% | −360.1% | −321.8% | −843.4% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +28.1% | −23.6% | −16.2% | +0.2% | +670.2% | — |
| Operating income growth | +27.9% | +27.2% | +24.6% | −30.4% | −61.7% | — |
| Net income growth | +2.2% | −44.0% | +31.9% | −12.1% | −193.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −53.5% | −84.9% | −79.2% | −137.9% | −136.3% | −28.8% |
| Return on assets | −18.4% | −47.3% | −44.5% | −49.7% | −1.5% | −9.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 282.6% | 55.7% | 255.3% | 40.3% | 614.3% | 170.0% |
| Net debt to equity | 262.8% | 25.5% | 95.6% | 3.3% | 22.7% | −136.5% |
| Current ratio | 4.4% | 31.1% | 103.2% | 419.2% | 89.4% | 137.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: PeopleBio / 피플바이오 / 304840 / KRX:304840
Source: KRX statistical information